Strides Pharma gets USFDA nod to market HIV drug
Strides Pharma Science said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Singapore-based Strides Pharma Global, a stepdown wholly-owned subsidiary of the company, has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the US Food & Drug Administration (USFDA), the drug firm said in a statement.
The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added.
As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US.
Shares of Strides Pharma Science ended 2.51 per cent up at Rs 508.20 apiece on the BSE on Wednesday.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
If you make RDs of Rs 5,000, Rs 10,000, Rs 15,000, and Rs 20,000 in post office, what will be your maturity amount?
Special Live Trading Session on Saturday: Know why BSE, NSE will remain open on May 18; check timings
RCB vs CSK IPL 2024 Ticket Booking Online: Where and how to buy RCB vs CSK tickets online - Check IPL Match 68 ticket price, other details
Women loco pilots speak about their struggle; many men have to be informed even for 'washroom break' in a moving train
Bandhan Bank Q4 FY24 Results Preview: PAT, interest income likely to grow in almost double digits; asset quality may improve
05:39 PM IST